Global Blood Therapeutics Inc
NASDAQ:GBT
Global Blood Therapeutics Inc
Cash from Financing Activities
Global Blood Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Global Blood Therapeutics Inc
NASDAQ:GBT
|
Cash from Financing Activities
$482.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$2.2B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Global Blood Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
482.5m
USD
Based on the financial report for Jun 30, 2022, Global Blood Therapeutics Inc's Cash from Financing Activities amounts to 482.5m USD.
What is Global Blood Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
28%
Over the last year, the Cash from Financing Activities growth was 499%. The average annual Cash from Financing Activities growth rates for Global Blood Therapeutics Inc have been 10% over the past three years , 28% over the past five years .